OCLG.007.HUGE ALERT.EXTREMELY UNDERVALUED.READ WHY:)DON.T MISS IT:)
1)THE STOCK SHOULD BE TRADING AROUND .17 PPS OR CAP OF $15 MILLION
LIKE 4 TIMES THE REVENUES OF 2014.
2)A REPORTING COMPANY TRADES ON OTCQB.HUGE.
3)O/S LESS THAN 90 MILLION AS OF JANUARY 2014.AND IF YOU SEE THE
CHART VOLUMES SINCE NOT MUCH TRADED.
4)CAP OF ONLY $630,000.UNREAL.EXTREMELY LOW.
5)OVER $ 4 MILLION IN REVENUES FOR 2014.READ PREVIOUS NEWS BELOW.
6)LAST Q REVENUES ALONE OVER $700,000.READ BELOW.
7)Oncologix provides FDA approved medical devices=HUGE READ BELOW.
8) Oncologix Closes $4,000,000 Revolving Credit Facility From Senior Lender.READ BELOW NEWS.
9)CHECK THIS OUT BELOW IT RUN FROM .01 TO .029 IN 7 TRADING DAYS ON ONLY 6 MILLION VOLUMES.VERIFY BELOW.THAT IS WHAT HAPPENS WHEN ONLY 90 O/S
10)LOOKS LIKE A BOTTOM HERE.CHECK CHART.
2014/01/16 0.018 0.029 0.018 0.027 1,633,574 0.027
2014/01/15 0.017 0.022 0.017 0.019 276,372 0.019
2014/01/14 0.012 0.022 0.012 0.020 1,258,643 0.020
2014/01/13 0.016 0.017 0.013 0.015 709,292 0.015
2014/01/10 0.020 0.023 0.015 0.020 1,058,249 0.020
2014/01/09 0.012 0.024 0.011 0.024 793,985 0.024
2014/01/08 0.013 0.016 0.010 0.013 687,834 0.013
Outstanding at January 5, 2014 IS 88,478,545 ONLY.
A/S 200 MILLION.
Revenues FOR 3 MONTHS ENDED NOV 2013 $724,632
The acquisition of Amian Health will provide the delivery of personal care services to Private Pay and Veterans clients with a market segment that Angels of Mercy did not serve. We will merge the Amian operations and selected personnel into Angels of Mercy existing operations and the combined synergies of both business entities will provide over $4.1 million in annual revenues, 228 employees and earnings to exceed $540,000 per year. This acquisition continues with our healthcare division strategy: to acquire healthcare services-related companies.
Wayne Erwin, CEO of Oncologix, stated, "We are delighted to secure a credit facility with TCA Global that will support our company's financing needs throughout 2014. This facility will assist us with vital working capital and provide the capital structure needed to further our corporate strategy of continued growth primarily by acquisitions in our Healthcare Services division."
Oncologix Closes $4,000,000 Revolving Credit Facility From Senior Lender
ALEXANDRIA, LA--(Marketwired - Jan 8, 2014) - Oncologix Tech Inc. (OTCQB: OCLG), announced today that it has closed on a $4,000,000 revolving line of credit. Under the terms of the agreement, TCA Global Credit Master Fund, L.P. committed to lend $4,000,000 through one of the Fund's Senior Secured Revolving Notes, with an initial draw of $500,000. The Company must meet specific monthly reporting and collateral requirements to further draw on the revolving credit facility
TCA Global is a short duration, absolute return fund specializing in senior secured lending to small, mainly listed companies in the U.S., Canada, Western Europe and Australia. The firm has a level of domestic and cross-border expertise, long-standing experience and funding innovations, as is reflected in the number of transactions completed. For more information see www.tcaglobalfund.com.
Oncologix operates and manufactures Class II medical device products and delivers Personal Healthcare Services nationally. For its clients, Oncologix provides FDA approved medical devices and State licensed healthcare services. For its shareholders, Oncologix operates profitable business divisions that build, maintain and nourish shareholder value. The Company's corporate mission is to be the best small cap medical device and healthcare services holding company in North America.
